09/02/2018 22:26:22

Adamas Announces New Employment Inducement Grant

Related content
20 Feb - 
Adamas Announces Declaratory Judgment Action Filed by O..
13 Feb - 
Adamas to Announce Fourth Quarter and Full Year 2017 Fi..
08 Feb - 
Adamas Announces Publication of Amantadine Immediate Re..

EMERYVILLE, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 42,250 shares of the company’s common stock, at a per share exercise price of $36.49, the closing trading price on February 7, 2018, and restricted stock units to acquire 8,625 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

Adamas is using its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. The company is building upon the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease, with a pipeline of differentiated investigational programs, which includes ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial-onset seizures in patients with epilepsy. Adamas’ goal is to create and commercialize a new generation of neurological medicines intended to lessen the burden of disease on patients, caregivers and society. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contact:

Ashleigh Barreto         

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

ir@adamaspharma.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Investec Bank plc : Form 8.5 (EPT/RI) - Melrose Industries Plc.

21/02/2018 10:28:16
  FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant ..

Alliance Trust PLC : Transaction in Own Shares

21/02/2018 07:00:17
21 February 2018  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 20 February 2018 the Company purchased for cancellation 100,000 ordinary shares of 2.5p each at a price of 726.2368p per share.  Therefore, the total number of voting rights in the Company is now 343,820,589.    The above figure (343,820,589) may be used by sha..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

20/02/2018 15:25:09
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bermuda Principles event merges science and business
2
Pöyry provides lenders technical advisory services as Cirebon 2 power plant project in Indonesia achieves financial close
3
UPDATE:  Youngevity Completes Acquisition of Nature Direct
4
TransAtlantic Petroleum Provides Investor Presentations and Marketing Process Update
5
Toscana Energy Announces 2017 Reserves and Review of Strategic Alternatives

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 February 2018 12:49:44
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180219.1 - EUROWEB1 - 2018-02-21 13:49:44 - 2018-02-21 12:49:44 - 1000 - Website: OKAY